A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508759-38-00

Acronym

HDP-102-01

Enrollment

Registered

2025-03-12

Start date

2025-06-04

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory B-cell Malignancies

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland, Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026